BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine

Phase 2negativepersonalized mRNA cancer vaccineNegative

AI Analysis

Summary

BioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine, shortly after Moderna and Merck announced positive Phase 3 results with their competing mRNA cancer vaccine approach in a different indication.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

Phase 2 trial terminated

Importance:7/10

Sentiment:

-0.80

mRNA vaccinepersonalized medicineoncologytrial terminationclinical development

Related Companies

$BNTX

Read the original article

Published by Endpoints News on August 28, 2026 2:49 PM

Read Original